Open AccessSafe administration of ipilimumab plus nivolumab to a dialysis patient with renal cell carcinoma
Author(s) -
Iwaki Takuya,
Niimi Aya,
Kano Masato,
Kurokawa Yoshiaki,
Yoshizaki Uran,
Nozaki Keina,
Nomiya Akira,
Miyazaki Hideyo,
Kume Haruki
Publication year - 2021
Publication title -
iju case reports
Language(s) - English
Resource type - Journals
ISSN - 2577-171X
DOI - 10.1002/iju5.12231
Subject(s) - nivolumab , medicine , ipilimumab , renal cell carcinoma , hemodialysis , dialysis , population , oncology , adverse effect , carcinoma , urology , surgery , cancer , immunotherapy , environmental health
The combination of ipilimumab plus nivolumab has been used as first‐line therapy for metastatic renal cell carcinoma. While it is well known that hemodialysis patients have a higher rate of renal cell carcinoma compared to the general population, no reports have described the safety of ipilimumab–nivolumab in metastatic renal cell carcinoma patients on hemodialysis. Case presentation A 73‐year‐old man with a 21‐year history of dialysis was referred to our department in 2019 for bilateral renal tumors and multiple lung nodules. He had already been diagnosed with bilateral renal tumors in 2015, without undergoing surgery due to comorbidities. In May 2019, contrast‐enhanced computed tomography revealed multiple lung metastases in addition to the existing renal tumors; consequently, he was treated with four doses of nivolumab–ipilimumab with no adverse events. Conclusion The combination of ipilimumab plus nivolumab was safely used in a hemodialysis patient with metastatic renal cell carcinoma.